Role for immune monitoring to tailor induction prophylaxis in pediatric heart recipients

Philip Taylor Thrush, Jeffrey G Gossett, John M Costello, Kathleen L. Matthews, Reem Nubani, Hardik Bhagat, Carl L Backer, Elfriede Pahl

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

rATG is used for HTx induction but is costly and associated with infection and PTLD. Hypothesis: Tailoring rATG induction with CD3 monitoring results in less infection, reduced costs, and similar rejection. Retrospective review of HTx recipients receiving rATG induction. Control cases received "usual" rATG dosing (1.5 mg/kg/day typically × 5 days). Starting in October 2009, absolute CD3 monitoring (target <25 cells/mm3) guided rATG dosing (study cases). Outcomes included first-year incidence of infection/rejection, direct costs of therapy, and incidence of PTLD/death. Study cases (n = 32) received fewer doses of rATG (median 4 vs. 5, p < 0.001) and less total rATG (median 3.2 vs. 7.4 mg/kg, p < 0.001) compared with controls (n = 17). There was no difference in incidence of infection, rejection, or patient survival during the first year post-HTx. There was one early death in both groups and one late case of PTLD in the control group. Drug savings were significant (median drug cost per patient $2718 vs. $4756, p < 0.001). CD3-tailored rATG induction in HTx recipients is associated with reduced drug costs and similar rates of rejection/infection. Longer follow-up will determine whether extended benefits are associated with this induction monitoring strategy.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalPediatric transplantation
Volume18
Issue number1
DOIs
StatePublished - Feb 1 2014

Keywords

  • antithymocyte globulin
  • heart transplant
  • induction immunosuppression
  • pediatric

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint Dive into the research topics of 'Role for immune monitoring to tailor induction prophylaxis in pediatric heart recipients'. Together they form a unique fingerprint.

  • Cite this

    Thrush, P. T., Gossett, J. G., Costello, J. M., Matthews, K. L., Nubani, R., Bhagat, H., Backer, C. L., & Pahl, E. (2014). Role for immune monitoring to tailor induction prophylaxis in pediatric heart recipients. Pediatric transplantation, 18(1), 79-86. https://doi.org/10.1111/petr.12193